Welcome Italia selects ADVA FSP 3000 for ultra-high-capacity enterprise services
30.7.2019 09:55:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Welcome Italia has selected its FSP 3000 and ALM fiber monitoring solution to enable assured high-capacity enterprise services throughout Italy. The technology partnership will create scalable fiber optic infrastructure and provide the security and reliability needed for IoT and 5G applications. Stretching over 2,500km and connecting Welcome Italia’s two main data centers, the new network features ADVA’s colorless, directionless and flexgrid multi-degree ROADMs, enabling automatic traffic rerouting for enhanced availability. The solution has also been primed for the comprehensive, low-latency security of ADVA’s ConnectGuard™ Optical encryption technology. ADVA’s partner Sirti is installing the network and will also provide ongoing maintenance and support.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190729005500/en/
Image ADVA's FSP 3000 and ALM fiber monitoring solution will play a key role in delivering assured high-capacity enterprise services throughout Italy (Photo: Business Wire)
”Our aim is to harness the best technology available to provide the ultimate service for our enterprise customers. ADVA’s scalable and efficient solution not only empowers us to deliver fast, flexible and secure business continuity services, but it also helps us reduce cost and lay the foundation for future growth,” commented Nicola Gallico, network manager and founder, Welcome Italia. “This deployment provides concrete answers to the most urgent needs of Italian enterprises. It means they can rely on high-speed, low-latency connectivity backed up by a fully redundant network architecture and protected by real-time fiber monitoring. With the support of the ADVA and Sirti team, we’ll continue to help our customers develop their businesses and seize new opportunities.”
Welcome Italia’s new backbone network serves enterprise clients throughout Italy with points of presence spread across the country. Built on the ADVA FSP 3000, it simplifies network operations and helps to reduce capital and operational expenditure. With its modular architecture, the FSP 3000 gives Welcome Italia the freedom to expand its network as soon as it’s required. The solution is also monitored by the ADVA ALM, which gives real-time insight into the integrity and performance of Welcome Italia’s fiber infrastructure, significantly improving robustness and efficiency. What’s more, the complete network is managed by Ensemble Controller, which combines efficiency in manual operations with programmatic control. This advanced management and domain control solution supports users while also enabling intelligent algorithms to gather data and take autonomous action.
“Welcome Italia chose our technology because it’s the ideal tool for meeting the needs of enterprise customers. It provides superb scalability and cost efficiency, enabling high-speed services that are secure and fully future proof. We’re pleased to be working closely with Welcome Italia’s team to ensure that businesses in this region can capitalize on the most advanced latency-sensitive applications as soon as they hit the market,” commented Marcello Forti, VP, sales, ADVA. “With the flexibility of our ROADM technology and our ALM providing complete fiber network visibility, this solution gives Welcome Italia a new level of agility and reliability. For enterprises across Italy, Welcome Italia’s new network will be the key to harnessing the business opportunities of the IoT.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.advaoptical.com.
About Welcome Italia
Welcome Italia is an Italian telecommunication operator that simplifies your company’s communications with an integrated offer of mobile and fixed line services called Vianova. Vianova combines traditional services, like telephony and ultra-broadband data access, with unified communication and collaboration services like cloud, centrex, mail, meetings, Wi-Fi calls, busy calls, SIM manager. Welcome Italia is also appreciated for the quality of its customer care that answers calls in three rings. Two property data centers host the redundant infrastructure that allows the supply of services for the whole Welcome Italia Group. www.welcomeitalia.it/en
Published by:
ADVA Optical Networking SE, Munich, Germany
www.advaoptical.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190729005500/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@advaoptical.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@advaoptical.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
